GSK has struck its largest-ever acquisition, agreeing to buy U.S. cancer drug developer Nuvalent for $10.6 billion in a transaction known inside the company as Project Nashville. The deal adds two late-stage lung cancer drug candidates to GSK’s pipeline - therapies that could receive U.S. approval within the year - and is slated to close in the third quarter.
The purchase aligns with CEO Luke Miels’ stated objective to expand GSK’s footprint in oncology. Miels, who assumed the chief executive role at the start of the year, has emphasized a measured rebuilding of the business. After the Nuvalent transaction was announced, Miels told a group of journalists that the company’s approach had been "a brick-by-brick building approach." The Nuvalent acquisition represents what one investor described as a "very large brick" in that construction.
GSK had left oncology in 2015 as part of an asset swap with Novartis valued at more than $16 billion. The turn back into cancer drug development began under the previous CEO and has included several smaller transactions: a $5.1 billion acquisition of Tesaro in 2018, the nearly $2 billion purchase of Sierra Oncology and a number of high-value licensing agreements. Executives say Nuvalent’s assets complement those earlier moves by delivering two late-stage assets that could provide near-term commercial opportunities.
Investors greeted the move as a substantive escalation in GSK’s commitment to oncology. James Eugene, an analyst at GSK shareholder Verso Investment Management, characterized Nuvalent as a substantial addition to the rebuild. Elena Meng, a portfolio manager at Gabelli Funds, said the acquisition’s scale was larger than GSK’s recent deals and that the oncology strategy appeared to be fully established; she described the difference as not the strategy itself but the size of the commitment.
An individual close to the negotiations said there had been competitive interest in Nuvalent prior to the agreement, and that competition helped push the agreed price to a roughly 40% premium over Nuvalent’s closing share price before the deal was announced. The person, who was not authorised to speak publicly, also noted that Nuvalent had been on the radar of large pharmaceutical companies for at least 18 months because it was one of only a few firms with late-stage oncology programs nearing potential approval.
Commercial and strategic implications
GSK expects the acquisition to help offset revenue pressures expected later this decade from patent expiries on products such as the HIV drug dolutegravir. Analysts estimate GSK’s total drug sales at approximately A334 billion ( $45.53 billion) for this year. Some investors have argued that the addition of de-risked products could together achieve peak sales in the $3 billion to $4 billion range, aiding the company’s ambition to reach A340 billion in annual sales by 2031.
GSK does not plan to contest every oncology niche dominated by large peers, and executives have said they view oncology as a potential growth area rather than a wholesale pivot. Tony Wood, the company’s chief scientific officer, said before the deal that "a specialty business without an oncology component is not a complete proposition." That comment underscores management’s view that the addition of oncology assets is necessary to round out the company’s specialty portfolio.
The Nuvalent assets target ROS1- and ALK-positive lung cancers. GSK will need to demonstrate that the therapies can compete with established treatments from other pharmaceutical companies and that they offer tolerability profiles acceptable to patients and prescribers. Barclays analysts noted the deal made strategic sense, but cautioned that neither of the two assets appeared to be a "mega blockbuster." The bank highlighted that smaller patient populations could nonetheless become meaningful opportunities if the drugs maintain patient adherence over long periods with fewer adverse effects than existing medicines.
Investor perspectives and next steps
Some shareholders view the return to oncology as a correction of a prior strategic mistake made when the company exited the sector in 2015 to focus on vaccines, respiratory products and consumer health. Markus Manns, a portfolio manager at Union Investment, described the 2015 divestment as a mistake and said that the Nuvalent purchase brought de-risked products capable of generating significant sales that would help counter losses of exclusivity in other therapeutic areas.
Not all observers expect GSK to close the gap with established oncology leaders. Ketan Patel, a fund manager at Whitefriars, described the deal as an important step but said the company will need to pursue additional acquisitions to meaningfully compete with larger incumbents such as Roche and Merck. He added that GSK may have to pay premium prices to acquire competitive assets in the future.
GSK will now transition into the integration phase for Nuvalent while continuing to monitor regulatory progress for the two lung cancer candidates. The company’s management will also face the task of determining how best to commercialize and position the therapies within the competitive landscape and how they fit into broader plans to achieve sales targets by 2031.
"Our strategy has been a brick-by-brick building approach," Miels said after the transaction was announced.
The transaction price, the near-term regulatory timeline for the drugs and the company’s longer-term pipeline-building strategy will remain focal points for investors as GSK moves to close the Nuvalent acquisition in the third quarter. The reported exchange rate in the announcement equates $1 to 0.7468 pounds, a conversion cited in the company commentary.